Andere talen Hangzhou Tigermed Consulting Co., Ltd

Aandelen

300347

CNE100001KV8

slotkoers Shenzhen S.E. Andere beurzen 00:00:00 24-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
52,6 ^CNY	-0,92%		-0,30%	-4,31%

29/03	Winst en omzet van Tigermed Consulting stijgen in 2023	MT
28/03	Hangzhou Tigermed Consulting Co, Ltd kondigt slotdividend aan voor het jaar eindigend op 31 december 2023, betaalbaar op 31 juli 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Borse Cina : chiudono miste, male Shanghai -0,7%, bene Hong Kong +1,92%	23/04
Tigermed Consulting's Profit, Revenue Climb in 2023	29/03
Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024	28/03
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes	21/03
China Healthcare Stocks Rally on Hopes for Government Support	14/03
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	14/03
Hangzhou Tigermed Consulting Plans Up to 1 Billion Yuan Share Repurchase; Shares Jump 4%	07/02
Hangzhou Tigermed Consulting Co., Ltd announces an Equity Buyback for CNY 1,000 million worth of its shares.	06/02
Hangzhou Tigermed Consulting Co., Ltd authorizes a Buyback Plan.	06/02
Hangzhou Tigermed Consulting's Profit Up 19% in Q3	27-10-23
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27-10-23
Tigermed Reports 2023 Interim Results	28-08-23
Tigermed Consulting's Profit Jumps 16.5% in H1	28-08-23
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	25-08-23
Tigermed Officially Opens International Headquarters in Hong Kong	17-08-23
Bioclub announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd	07-08-23
Hangzhou Tigermed Consulting Co., Ltd. Announces Final Profit Distribution Plan Implementation (A Shares) for 2022, Payable on 07 July 2023	04-07-23
Hangzhou Tigermed Consulting Co. Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2022, Payable on 07 July 2023	26-06-23
Chengdu WestGene Biomedical Technology Co., Ltd. announced that it has received $63.25 million in funding from Qingdao Honline Huaxin Asset Management Co., Ltd., Beijing Konruns Pharmaceutical Co.,Ltd., Hangzhou Tigermed Consulting Co., Ltd, Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd., Yingke Innovation Asset Management Co., Ltd.	20-06-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hangzhou Tigermed Consulting Co., Ltd

Aandelen

300347

CNE100001KV8

Andere talen

Filters